Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Phase 4 Unknown 66 enrolled Beijing Tsinghua Chang Gung Hospital

NaSingle-groupOpen-labelTreatment

Summary

Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor effects on liver cancer. This study aims to further verify the effect and safety of recombinant human adenovirus type 5 combined with HAIC in the treatment of intrahepatic mass-forming cholangiocarcinoma.

Timeline

Start: 2022-08-01
Primary completion: 2026-04-01
Completion: 2026-04-01

Publications

Blair AB, Alobuia WM, Palta M, Raman SS, Levine MH, Benson AB 3rd, D'Angelica MI, Cloyd JM. Locoregional Treatment Options for Locally Advanced Intrahepatic Cholangiocarcinoma. J Natl Compr Canc Netw. 2025 Aug 14;23(9):e257085. doi: 10.6004/jnccn.2025.7085.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	H101	Other / unclassified	5e+11 unknown	Other
Subject	H101	Other / unclassified	1e+12 unknown	Other
Subject	H101	Other / unclassified	1.5e+12 unknown	Other
Background	Leucovorin	Small molecule	—	—
Background	Oxaliplatin	Small molecule	50 mg	—
Background	fluorouracil	Small molecule	1.5 g	—

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Summary

Timeline

Publications

Drugs

Indications